X
NTLA icon

Xponance’s Intellia Therapeutics NTLA Stock Holding History

Xponance’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,163
Closed -$211K – 1262
2023
Q2 		$211K Buy
+5,163
New +$209K ﹤0.01% 1136
2022
Q4 		– Sell
-4,250
Closed -$238K – 1240
2022
Q3 		$238K Buy
4,250
+210
+5% +$13K ﹤0.01% 1057
2022
Q2 		$209K Buy
4,040
+732
+22% +$37.2K ﹤0.01% 1085
2022
Q1 		$240K Buy
3,308
+14
+0.4% +$1.19K ﹤0.01% 1068
2021
Q4 		$389K Buy
3,294
+47
+1% +$5.89K 0.01% 990
2021
Q3 		$436K Sell
3,247
-251
-7% -$38K 0.01% 942
2021
Q2 		$566K Buy
+3,498
New +$272K 0.01% 868

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Xponance's NTLA Position: Q3 2023 in Review

Xponance sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 5,163 shares — an estimated $211K sold.

Xponance first reported a position in NTLA in Q2 2021 and held it in 7 quarters. The position peaked at $566K in Q2 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

  • Xponance reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Xponance sold 5,163 Intellia Therapeutics shares in Q3 2023, an estimated $211K.
  • Xponance first reported a position in Intellia Therapeutics in Q2 2021 and held it in 7 quarters.
  • Xponance's Intellia Therapeutics position peaked at $566K in Q2 2021.
  • 284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on Xponance's 13F filing for Q3 2023, filed 24 Oct 2023.